PD-1 Antitumor Immunity against Murine H22 Hepatocarcinoma In vivo

PD-1 Antitumor Immunity against Murine H22 Hepatocarcinoma In vivo

Loading document ...
Loading page ...


Author(s): Leilei Liang, Fuping Guan, Yinlin Ge

Download Full PDF Read Complete Article

DOI: 10.18483/ijSci.1591 167 460 71-76 Volume 7 - Mar 2018


Objective: To explore the role of PD-1 expression level on the growth of hepatocarcinoma line H22. Methods: Tumor-bearing mice model was established with H22 cells in ICR mice. The model mice were randomly divided into two groups, control group and PD-1 interference group (PD-1-siRNA). The control group was injected transfection reagent, wherase the PD-1-siRNA was given the transfection reagent with PD-1-siRNA. Observed the life condition and tumor growth of mice, measured and recorded the tumor volume. The mRNA expression levels of PD-L1, PD-L2, P53, caspase-3 and IL-6 in tumor tissue were detected by real time fluorescence quantitative PCR (qPCR) technique. The expression of IFN-γ cytokines in spleen and tumor tissue was detected by ELISA. The ratio of Bax and Bcl-2 protein was detected by Western Blot to analyze the effect of PD-1-siRNA on tumor cell apoptosis. Results: Compared with control group, mice of PD-1-siRNA in better quality of life, survival time prolonged and the tumor volume of mouse was significantly reduced. The mRNA expression levels of PD-L1, PD-L2, P53 and caspase-3 were increased, others, IL-6 expression level was significantly decreased. The expression level of IFN-γ was up-regulated in spleen and tumor tissues. Western blot shown that the ratio of Bax and Bcl-2 was significantly increased. Conclusion: Interfere of PD-1 expression can effectively inhibit the growth of hepatocarcinoma cell H22 in mice.


PD-1-siPD-1, PD-L1, Immunotherapy, H22 hepatoma cells, IFN-γ


  1. Jemal A, Bray F, Center M M, et al. Global cancer statistics. CA. Cancer J Clin[J]. Ca A Cancer Journal for Clinicians, 2011, 61(2): 69-90.
  2. Ansell S M, Lesokhin A M, Borrello I, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma[J]. The New England journal of medicine, 2015, 372(4): 311-319.
  3. Swaika A, Hammond W A, Joseph R W. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy[J]. Molecular Immunology, 2015, 67(2, Part A): 4-17.
  4. Kim J M, Chen D S. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)[J]. Annals of Oncology, 2016, 27(8): 1492-1504.
  5. Patsoukis N, Brown J, Petkova V, et al. Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation[J]. Science signaling, 2012, 5(230): ra46-ra46.
  6. Ma W, Gilligan B M, Yuan J, et al. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy[J]. Journal of Hematology & Oncology, 2016, 9: 47.
  7. Chauvin J-M, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen–specific CD8(+) T cells in melanoma patients[J]. The Journal of Clinical Investigation, 2015, 125(5): 2046-2058.
  8. Smyth M J, Ngiow S F, Ribas A, et al. Combination cancer immunotherapies tailored to the tumour microenvironment[J]. Nature Reviews Clinical Oncology, 2015, 13: 143.
  9. Buchbinder E I, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition[J]. American Journal of Clinical Oncology, 2016, 39(1): 98-106.
  10. Reck M, Rodríguez-Abreu D, Robinson A G, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer[J]. New England Journal of Medicine, 2016, 375(19): 1823-1833.
  11. Meng X, Huang Z, Teng F, et al. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy[J]. Cancer Treatment Reviews, 2015, 41(10): 868-876.
  12. Eyre T A, Collins G P. Immune checkpoint inhibition in lymphoid disease[J]. British Journal of Haematology, 2015, 170(3): 291-304.
  13. Shih K-S, Lin C-C, Hung H-F, et al. One-Step Chromatographic Purification of Helicobacter pylori Neutrophil-Activating Protein Expressed in Bacillus subtilis[J]. PLoS ONE, 2013, 8(4): e60786.
  14. Rusolo F, Pucci B, Colonna G, et al. Evaluation of Selenite Effects on Selenoproteins and Cytokinome in Human Hepatoma Cell Lines[J]. Molecules, 2013, 18(3): 2549.
  15. Park H J, Kusnadi A, Lee E-J, et al. Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors[J]. Cellular Immunology, 2012, 278(1): 76-83.
  16. Jansson M D, Damas N D, Lees M, et al. miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2[J]. Oncogene, 2014, 34: 1908.
  17. Ramani P, Nash R, Rogers C A. Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma[J]. Histopathology, 2015, 66(3): 370-379.
  18. Fuchs E J, Mckenna K A, Bedi A. p53-dependent DNA Damage-induced Apoptosis Requires Fas/APO-1-independent Activation of CPP32β[J]. Cancer Research, 1997, 57(13): 2550-2554.
  19. Khalil H, Bertrand M J M, Vandenabeele P, et al. Caspase-3 and RasGAP: a stress-sensing survival/demise switch[J]. Trends in Cell Biology, 2014, 24(2): 83-89.
  20. Steller H. Mechanisms and genes of cellular suicide[J]. Science, 1995, 267(5203): 1445-1449.
  21. Tagliamonte M, Petrizzo A, Tornesello M L, et al. Combinatorial immunotherapy strategies for hepatocellular carcinoma[J]. Current Opinion in Immunology, 2016, 39: 103-113.
  22. Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives[J]. Expert Review of Anticancer Therapy, 2014, 14(10): 1205-1218.

Cite this Article:

International Journal of Sciences is Open Access Journal.
This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Author(s) retain the copyrights of this article, though, publication rights are with Alkhaer Publications.

Search Articles

Issue June 2023

Volume 12, June 2023

Table of Contents

World-wide Delivery is FREE

Share this Issue with Friends:

Submit your Paper